Welcome to the Hawaii Chapter of the American College of Cardiology2026 Conference Click here to learn about our annual Chapter meeting April 25, 2026 Click here to download the flyer |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- HTI-5 Final Rule Released: ONC Health IT Certification Program, Information Blocking Updates, MoreThe Office of the National Coordinator for Health IT (ONC) released the Health Data, Technology and Interoperability: ONC Deregulatory Actions to Unleash Prosperity (HTI-5) final rule, building on the HTI-5 proposed rule from December 2025, to streamline the ONC Health IT Certification Program, update information blocking regulations and support AI-enabled FHIR-based interoperability.
- Is TTE-Guided Permanent Pacemaker Implantation Feasible Without Fluoroscopy?Transthoracic echocardiography (TTE)-guided permanent pacemaker implantation without fluoroscopy was feasible in patients with adequate supine acoustic windows, according to a prospective, single-center study recently published in JACC: Advances.
- Black Adults in Disadvantaged Neighborhoods Less Likely to Be Diagnosed With AFibAmong individuals living in more disadvantaged neighborhoods, non-Hispanic Black adults were less likely to be diagnosed with atrial fibrillation (AFib) than non-Hispanic White adults, according to a cohort study of Medicare Advantage and commercially insured individuals published Oct. 23 in JAMA Network Open.
- Can Echocardiographic Evaluation of Severe MR Be More Efficient?Certain criteria from the American Society of Echocardiography (ASE) guidelines, such as pulmonary vein systolic reversal and left ventricle (LV) remodeling parameters, are "highly specific" for diagnosing severe mitral regurgitation (MR) even when less than four criteria are present, according to a recent study published in JACC: Cardiovascular Imaging.
- Frailty and Sarcopenia in HFpEF: Considerations For GLP1RAsHeart failure with preserved ejection fraction (HFpEF) affects an estimated 3 million people in the United States and up to 32 million worldwide, with an estimated lifetime risk of heart failure (HF) exceeding 10% at 45 years of age in both men and women.


